Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more
Gland Pharma Limited (GLAND) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.062x
Based on the latest financial reports, Gland Pharma Limited (GLAND) has a cash flow conversion efficiency ratio of 0.062x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹5.93 Billion) by net assets (₹95.63 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gland Pharma Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Gland Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Gland Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gland Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Longboard Pharmaceuticals Inc
NASDAQ:LBPH
|
-0.075x |
|
X Trade Brokers Dom Maklerski SA
WAR:XTB
|
0.044x |
|
O-I Glass Inc
NYSE:OI
|
0.174x |
|
Region Group
AU:RGN
|
0.031x |
|
Sharp Corporation
PINK:SHCAF
|
0.014x |
|
Universal Technical Institute Inc
NYSE:UTI
|
0.174x |
|
Intea Fastigheter B
ST:INTEA-B
|
N/A |
|
Insignia Financial Ltd
AU:IFL
|
0.091x |
Annual Cash Flow Conversion Efficiency for Gland Pharma Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Gland Pharma Limited from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹91.51 Billion | ₹9.15 Billion | 0.100x | -12.51% |
| 2024-03-31 | ₹87.24 Billion | ₹9.97 Billion | 0.114x | +149.85% |
| 2023-03-31 | ₹79.59 Billion | ₹3.64 Billion | 0.046x | -58.61% |
| 2022-03-31 | ₹71.58 Billion | ₹7.91 Billion | 0.110x | +7.81% |
| 2021-03-31 | ₹59.03 Billion | ₹6.05 Billion | 0.102x | -46.69% |
| 2020-03-31 | ₹36.46 Billion | ₹7.01 Billion | 0.192x | +196.98% |
| 2019-03-31 | ₹28.62 Billion | ₹1.85 Billion | 0.065x | -22.80% |
| 2018-03-31 | ₹24.10 Billion | ₹2.02 Billion | 0.084x | -63.22% |
| 2017-03-31 | ₹20.90 Billion | ₹4.76 Billion | 0.228x | -- |